Skip to main content
Home Printable Version Mepha Switzerland
Skip navigation links
for treatment - Plasmotrim 

Plasmotrim™ Rectocaps™

Plasmotrim™ Rectocaps™  is a highly innovative rectal artesunate mono substance for the initial (pre-referral) treatment of severe malaria. Plasmotrim™ Rectocaps™ is the only rectal artesunate available in two dosage strengths with an innovative galenic formulation: Plasmotrim™ Rectocaps™ are thermostable and patent protected.

Plasmotrim™ Rectocaps™ listed on WHO essential drug list for children.

The therapeutic performance of Plasmotrim™ Rectocaps™

Plasmotrim™ Rectocaps™ act very fast and provide rapid fever clearance - Plasmotrim™ Rectocaps™ offer a very rapid symptomatic response. Pre-referral treatment must be supplemented and/or followed by effective oral or parenteral drug therapy as soon as possible. 

The tolerability of Plasmotrim™ Rectocaps™

Plasmotrim™ has an excellent overall tolerability and provides a quick stabilization of the patient’s general condition - There are no reports on cases of human embryotoxicity or teratogenicety. Artesunate does not negatively interact with other drugs.

The dosage scheme of Plasmotrim™ Rectocaps™

50 mg Rectocaps™ (children): to be adjusted according to bodyweight:
< 40 kg bodyweight (kg BW): 10 mg/kg BW

200 mg Rectocaps™ (adults):
40-59 kg BW: 400 mg
60-80 kg BW: 800 mg
> 80 kg BW: 1200 mg


 Factsheet

plasmotrim-factsheet060913 rev  July 08 (2).pdf

Disclaimer | Sitemap © 2000 - 2008 Mepha Ltd.